Certainly a good half IMO.
I thought there might be a Masters closure boost in the numbers, and the H2 outlook looked a bit dour to me, with mentions of costs going up from China. I suspect a rough NPAT excl the $3.1m write-back of about 135.5 for FY, with H2 not as shiny.
- Forums
- ASX - By Stock
- DLX
- Ann: Half Year Report 2017 - Appendix 4D
Ann: Half Year Report 2017 - Appendix 4D, page-3
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online